Answers are grounded in this paper and cite their sources.
Population pharmacokinetic analysis evaluates CYP2B6 activity in kidney disease patients, highlighting vitamin D's role.
Objective The aim of this study was to use bupropion as a cytochrome P450 (CYP) 2B6 probe to determine CYP2B6 function by using a population pharmacokinetic approach of parent bupropion and metabolite hydroxybupropion to explore the impacts of chronic kidney disease (CKD) and vitamin D status in patients and control subjects. Methods Plasma concentration data from 19 subjects after administration of 150 mg of sustained‐release bupropion were used in pharmacokinetic modeling. Blood samples were collected pre‐dose and serially post‐dose and analyzed by LC‐MS/MS. Population pharmacokinetic analysis was conducted using nonlinear mixed‐effect modeling (Phoenix NLME v8.6.1.6, Certara Inc.). A separate post hoc analysis evaluated the formation clearance of hydroxybupropion as an assessment of CYP 2B6 functional activity. Results The final model was composed of 2 compartments with first‐order formation and elimination for bupropion and hydroxybupropion. A multiplicative error model explained residual variability. Covariates tested in the model, including vitamin D baseline concentrations and CKD, did not have a significant impact on the pharmacokinetics of bupropion and hydroxybupropion. Model validation was performed using visual predictive check. A trend toward increased formation clearance was observed within the CKD group (2.21 L/h vs. 2.65 L/h, p = 0.39) and a slight reduction in the control group (2.96 L/h vs. 2.66 L/h, p = 0.85) with vitamin D repletion vs. insufficiency. Conclusion The study contributes to the understanding of CYP 2B6 function in CKD and exhibited increased CYP2B6 function in CKD subjects with vitamin D repletion.
No takes yet. Share an insight, caveat, or question.
Ghimire et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: